Does Fallon Community Health Plan (FCHP) Cover Vyvanse?

What Is Vyvanse and Why Does Insurance Coverage Matter?

Vyvanse (lisdexamfetamine dimesylate) is a central nervous system stimulant approved by the FDA in 2007 for attention-deficit/hyperactivity disorder (ADHD) in adults and children aged 6 and older, and in 2015 for moderate-to-severe binge eating disorder (BED) in adults. [1] It works as a prodrug: the body converts lisdexamfetamine into d-amphetamine after oral ingestion, which then increases synaptic dopamine and norepinephrine availability. [2]

Because Vyvanse launched as a branded Schedule II controlled substance, it has historically occupied a non-preferred tier on most commercial formularies, producing high out-of-pocket costs for patients who lack adequate coverage.

Why This Drug Is Expensive Without Coverage

The brand-name list price for a 30-count supply of Vyvanse 30 mg capsules averages roughly $400 at U.S. Retail pharmacies. For patients paying entirely out of pocket, annual costs may exceed $4,800. The FDA approved the first generic lisdexamfetamine dimesylate products in 2023, which has modestly reduced market prices, but brand-name Vyvanse remains the most commonly prescribed form. [3]

ADHD Prevalence and Treatment Rates

An estimated 8.1% of U.S. Adults meet DSM-5 criteria for ADHD, according to data published in the American Journal of Psychiatry. [4] Among adults with ADHD who are treated pharmacologically, amphetamine-class stimulants are first-line agents per the American Academy of Child and Adolescent Psychiatry (AACAP) practice parameters. [5] This clinical demand makes stimulant coverage decisions by insurers such as FCHP directly relevant to millions of patients.

How FCHP Formularies Are Structured

FCHP is a Massachusetts-based nonprofit health plan that offers commercial, Medicare Advantage, and Medicaid-managed care (MassHealth) products. Each product line maintains a separate drug formulary, meaning Vyvanse coverage rules differ depending on which specific FCHP product a member holds.

Tier Placement for Vyvanse

Most commercial and Medicare Advantage formularies place brand-name Vyvanse at Tier 3 (preferred brand) or Tier 4 (non-preferred brand). Tier 3 cost-sharing typically runs $60, $100 per 30-day fill; Tier 4 may run $100, $200 or higher before the deductible is met. MassHealth (Medicaid) formularies list drugs differently and may require additional criteria under Massachusetts Medicaid drug policy. [6]

Generic lisdexamfetamine, where listed, usually appears at Tier 2 (preferred generic), which reduces member cost substantially.

Controlled Substance Formulary Rules

Because Vyvanse is a Schedule II substance under the Controlled Substances Act, federal and state rules add additional dispensing restrictions beyond standard formulary management. [7] Pharmacies cannot dispense more than a 30-day supply at one time, and electronic prescribing of controlled substances (EPCS) is mandatory in Massachusetts. These regulatory constraints are separate from insurance prior authorization and operate in parallel.

Prior Authorization Requirements for Vyvanse Under FCHP

Prior authorization (PA) is the process by which a health plan reviews whether a prescribed drug meets clinical criteria before agreeing to pay. FCHP, like nearly all commercial insurers, requires PA for Vyvanse across most plan types.

Typical Clinical Criteria FCHP Requests

Although FCHP updates its PA criteria periodically, the criteria it uses for stimulants are generally consistent with industry-wide standards. Prescribers typically must document:

• A confirmed DSM-5 diagnosis of ADHD or moderate-to-severe BED supported by standardized rating scales (e.g., Adult ADHD Self-Report Scale, Conners' Rating Scales) [8]
• Patient age eligibility (6 years or older for ADHD; 18 or older for BED)
• Absence of contraindications such as structural cardiac abnormalities, severe hypertension, or current use of monoamine oxidase inhibitors [1]
• Prescriber specialty or attestation that ADHD/BED evaluation was performed
• Prior medication history, particularly for step therapy requirements

Step Therapy: The Trial-First Barrier

Step therapy, sometimes called "fail-first," requires a patient to try and fail a less expensive drug before the insurer will cover the requested agent. For Vyvanse, FCHP and most comparable plans require at least one prior trial of a generic stimulant, typically:

1. Mixed amphetamine salts (generic Adderall or Adderall XR)
2. Methylphenidate hydrochloride (generic Ritalin, Concerta, or similar)

The American Academy of Pediatrics 2019 ADHD clinical practice guideline endorses stimulants broadly as first-line pharmacotherapy without mandating a specific stimulant first. [9] This means a clinician may argue that a patient's clinical profile (e.g., prior adverse response to methylphenidate) justifies bypassing step therapy through a step-therapy exception request.

Massachusetts state law (MGL Chapter 176T, the "Step Therapy" statute) requires health plans to grant a step-therapy exception if the alternative drug has been tried previously and caused adverse effects, is contraindicated, or is expected to be clinically ineffective based on patient-specific factors. [10]

How to Submit a Prior Authorization Request

The prescriber, not the patient, submits the PA to FCHP. The typical workflow is:

1. The pharmacy attempts to fill the prescription and receives a "prior authorization required" reject code.
2. The pharmacy notifies the prescriber or the prescriber's office.
3. The prescriber submits a PA request through FCHP's provider portal, by fax, or through a clearinghouse such as CoverMyMeds.
4. FCHP is required under Massachusetts law to return an initial determination within 72 hours for non-urgent requests and 24 hours for urgent clinical situations. [11]

What Happens If FCHP Denies Coverage?

A PA denial is not the end of the road. Patients and prescribers have several structured options.

Internal Appeal

Under Massachusetts law and the federal Patient Protection and Affordable Care Act (ACA), members may file an internal appeal within 180 days of receiving a denial notice. FCHP must respond to a standard appeal within 30 days. An expedited appeal (for urgent situations) must be resolved within 72 hours. [12]

The appeal should include:

• A detailed letter of medical necessity from the prescriber
• Objective diagnostic documentation (e.g., rating scale scores, neuropsychological testing if available)
• Documentation of any prior medication trials and their outcomes
• Peer-reviewed literature supporting Vyvanse specifically, such as the key Phase 3 trial by Wigal et al. (2010) demonstrating significantly greater ADHD symptom reduction with lisdexamfetamine versus placebo on the ADHD Rating Scale IV (P<0.001) [13]

External Review

If the internal appeal is denied, Massachusetts residents may request an Independent Medical Review (IMR) through the Massachusetts Division of Insurance (DOI). An independent reviewer who is board-certified in a relevant specialty examines whether the denial was clinically appropriate. This process is free to members and legally binding on the health plan. [14]

Step-Therapy Exception Under Massachusetts Law

As noted, MGL Chapter 176T entitles members to a step-therapy exception when any of the statutory override criteria are met. The prescriber should explicitly cite the specific criterion (adverse drug reaction, contraindication, or expected clinical ineffectiveness) in writing when submitting the exception request. Generic documentation such as "patient prefers Vyvanse" does not meet the legal threshold.

Vyvanse for Binge Eating Disorder: Additional Coverage Considerations

Vyvanse is the only FDA-approved pharmacotherapy for moderate-to-severe BED in adults, as designated in the FDA approval from January 30, 2015. [1] Despite this status, some formularies apply more restrictive criteria for the BED indication than for ADHD.

BED Diagnosis Requirements

For BED coverage, FCHP's PA criteria typically require:

• A confirmed DSM-5 BED diagnosis by a qualified clinician
• Documentation of episode frequency (at least 1 binge episode per week for 3 months per DSM-5 criteria) [15]
• Ruling out of other eating disorders (anorexia nervosa, bulimia nervosa)
• Absence of significant cardiovascular risk factors, given Vyvanse's sympathomimetic properties

Evidence Base That Supports Medical Necessity Letters

The key BED trials (SPD489-343 and SPD489-344) enrolled 765 adults and demonstrated that lisdexamfetamine 50 mg and 70 mg reduced binge eating days per week by approximately 3.9 versus 1.3 for placebo (P<0.001). [16] Citing these trial numbers in a medical necessity letter strengthens the clinical case considerably.

Cost-Reduction Strategies When Coverage Is Limited

Even when FCHP covers Vyvanse, copays may be substantial. Several cost-reduction pathways exist.

Manufacturer Savings Card

Takeda Pharmaceuticals (Vyvanse's manufacturer) has historically offered a savings card that reduces the brand-name copay to as little as $30 per fill for commercially insured patients. This card does not apply to federal or state government insurance programs, including Medicare and Medicaid. Eligibility and card terms change periodically; patients should verify current offers at the manufacturer's website.

Generic Lisdexamfetamine

The FDA approved generic lisdexamfetamine dimesylate in 2023. [3] Patients on FCHP commercial plans may pay significantly less with the generic version if it is placed at a lower tier. Prescribers can write "substitution permitted" on the prescription to allow pharmacy dispensing of the generic.

GoodRx and Third-Party Discount Programs

GoodRx and similar discount programs can reduce cash prices for generic lisdexamfetamine to $80, $150 per 30-count supply at major pharmacy chains, a savings of roughly 60 to 70% off brand-name list price. Patients should be aware that using a discount card instead of insurance means the cost does not count toward the health plan deductible or out-of-pocket maximum.

340B Program Pharmacies

Patients who receive care at a federally qualified health center (FQHC) or other 340B-covered entity may access medications, including lisdexamfetamine generics, at substantially reduced prices through the 340B Drug Pricing Program administered by HRSA. [17]

Clinical Evidence Supporting Vyvanse Use

Insurance coverage decisions are rooted partly in the clinical evidence base. Understanding that evidence helps prescribers construct stronger PA and appeal documents.

ADHD Efficacy Data

The key Phase 3 registration trial for Vyvanse in adults (SPD489-301, N=420) showed statistically significant reductions in ADHD Rating Scale IV (ADHD-RS-IV) total scores compared to placebo at week 4 (mean difference: 16.2 points, P<0.001). [13] This magnitude of effect is clinically meaningful, given that a change of 8.9 points is considered the minimum clinically important difference on the ADHD-RS-IV. [18]

A meta-analysis published in The Lancet Psychiatry (2018) covering 133 randomized controlled trials and 81 trials with usable data (N=10,068 participants) ranked amphetamines as among the most effective pharmacological agents for ADHD in adults based on standardized mean differences. [19]

Cardiovascular Safety Signal

The FDA requires a boxed warning for all amphetamine-class stimulants regarding cardiovascular risk and abuse potential. [1] A 2023 cohort study published in JAMA (N=278,519) found that adults initiating stimulant treatment did not have a significantly higher incidence of serious cardiovascular events compared to non-users over 6 years of follow-up (adjusted hazard ratio 0.96, 95% CI 0.87 to 1.06). [20] This data point may support medical necessity letters addressing cardiovascular concerns raised by reviewers.

Functional Outcomes in Adults

Beyond symptom scales, lisdexamfetamine has demonstrated improvement in executive function measures. A 4-week double-blind trial published in CNS Drugs (2011, N=142) showed statistically significant improvement on the Behavior Rating Inventory of Executive Function (BRIEF) Adult Self-Report versus placebo (P<0.001). [21]

FCHP Medicare Advantage and MassHealth Coverage Differences

Medicare Advantage Plans

FCHP's Medicare Advantage products are subject to CMS formulary requirements. CMS mandates that Medicare Part D plans cover at least two drugs in each drug class. Stimulants are not classified as a protected class under Part D (protected classes include antidepressants, antipsychotics, anticonvulsants, immunosuppressants, antiretrovirals, and antineoplastics). [22] As a result, Medicare Advantage plans including FCHP's have more flexibility to restrict, tier up, or require PA for Vyvanse.

Medicare beneficiaries with ADHD should check the annual Evidence of Coverage document for their specific FCHP Medicare plan, as formularies change each January 1.

MassHealth (Medicaid)

MassHealth follows Massachusetts Medicaid drug policy for stimulant coverage. The MassHealth Pharmacy Program publishes preferred drug lists (PDLs) that change quarterly. Generic lisdexamfetamine may be listed as preferred. Members should contact MassHealth member services or their prescriber to confirm current PDL status before filling.

A Step-by-Step Coverage Framework for FCHP Members Seeking Vyvanse

The following decision pathway synthesizes FCHP formulary rules, Massachusetts step-therapy statute, and ACA appeal rights into a practical sequence. This framework was developed by the HealthRX clinical team based on current MA insurance law and standard commercial formulary architecture.

Step 1. Confirm diagnosis and documentation. The prescriber should record DSM-5 criteria, rating scale scores, and functional impairment in the medical record before submitting any prescription.

Step 2. Check the current FCHP formulary. Log in to the FCHP member portal or call member services to confirm Vyvanse's current tier and whether PA is required for your specific plan.

Step 3. Submit the PA proactively. The prescriber's office should submit the PA before or simultaneously with the prescription to avoid a dispensing delay.

Step 4. If PA is denied, review the denial reason. Common denial reasons include step-therapy not completed, diagnosis not substantiated, or prescriber not meeting specialty criteria. Each reason has a targeted counter-argument.

Step 5. File a step-therapy exception if applicable. If the patient previously tried and failed generic stimulants, invoke MGL Chapter 176T explicitly in the exception request.

Step 6. File an internal appeal. Attach the prescriber's letter of medical necessity, peer-reviewed citations (e.g., [13], [16], [19]), and all supporting records.

Step 7. Request external IMR through the MA Division of Insurance if the internal appeal is denied. File at mass.gov/orgs/division-of-insurance within the required timeframe.

Step 8. Explore cost-reduction options in parallel. While awaiting a coverage decision, evaluate the manufacturer savings card, generic lisdexamfetamine, or 340B program access to avoid treatment gaps.

Prescriber Documentation Tips That Improve Approval Rates

Incomplete documentation is the most common cause of PA denials. The following specific documentation practices consistently improve approval rates across commercial formularies.

Use Validated Rating Scales

Insurers respond better to objective data than narrative descriptions. The Adult ADHD Self-Report Scale (ASRS v1.1), developed in partnership with the World Health Organization, is a validated 18-item screener with a sensitivity of 68.7% and specificity of 99.5% for adult ADHD at the standard cut-off. [23] Attaching a completed ASRS to the PA form provides objective evidence of diagnosis.

Quantify Functional Impairment

Document specific areas of functional impairment, such as occupational errors, driving incidents, or failed academic performance. The Weiss Functional Impairment Rating Scale (WFIRS) provides a standardized measure across five domains and is accepted by most clinical reviewers. [24]

Reference Prior Treatment Failures Specifically

Instead of writing "patient failed Adderall," write "patient trialed mixed amphetamine salts extended-release 20 mg daily for 6 weeks from [date] to [date]; discontinued due to pronounced afternoon rebound irritability and insomnia, documented in visit notes dated [date]." Specificity reduces the chance of a formulary reviewer requesting additional information.